T. Rowe Price Associates
DNA icon

T. Rowe Price Associates’s Ginkgo Bioworks DNA Stock Holding History

T. Rowe Price Associates’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$927K Sell
93,528
-8,783
-9% -$73.5K ﹤0.01% 2372
2026
Q1 		$628K Buy
102,311
+7,438
+8% +$61.9K ﹤0.01% 2351
2025
Q4 		$789K Buy
94,873
+1,869
+2% +$20.1K ﹤0.01% 2182
2025
Q3 		$1.36M Buy
93,004
+5,111
+6% +$61.2K ﹤0.01% 1924
2025
Q2 		$990K Buy
87,893
+13,613
+18% +$105K ﹤0.01% 1987
2025
Q1 		$424K Sell
74,280
-8,535
-10% -$87K ﹤0.01% 2320
2024
Q4 		$814K Buy
82,815
+3,152
+4% +$27K ﹤0.01% 2061
2024
Q3 		$651K Buy
79,663
+4,718
+6% +$47.3K ﹤0.01% 2150
2024
Q2 		$991K Sell
74,945
-7,511
-9% -$224K ﹤0.01% 1897
2024
Q1 		$3.83M Sell
82,456
-4,222
-5% -$219K ﹤0.01% 1302
2023
Q4 		$5.86M Buy
86,678
+500
+0.6% +$30.6K ﹤0.01% 1176
2023
Q3 		$6.24M Buy
86,178
+305
+0.4% +$24.4K ﹤0.01% 1142
2023
Q2 		$6.39M Sell
85,873
-1,349
-2% -$79.9K ﹤0.01% 1149
2023
Q1 		$4.64M Sell
87,222
-14,249
-14% -$903K ﹤0.01% 1203
2022
Q4 		$6.86M Sell
101,471
-3,927
-4% -$361K ﹤0.01% 1119
2022
Q3 		$13.2M Buy
105,398
+657
+0.6% +$78.3K ﹤0.01% 1016
2022
Q2 		$9.97M Sell
104,741
-116,038
-53% -$14.2M ﹤0.01% 1319
2022
Q1 		$35.6M Buy
220,779
+164,045
+289% +$31.9M ﹤0.01% 1078
2021
Q4 		$18.9M Buy
56,734
+49,436
+677% +$23.5M ﹤0.01% 1299
2021
Q3 		$3.38M Buy
+7,298
New +$3.55M ﹤0.01% 1575

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates's DNA Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Ginkgo Bioworks (DNA) stake by 8.6% in Q2 2026, selling an estimated $73.5K and leaving 93,528 shares worth $927K. The position accounts for ﹤0.01% of the portfolio, ranked #2372.

T. Rowe Price Associates first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $35.6M in Q1 2022. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • T. Rowe Price Associates held 93,528 shares of Ginkgo Bioworks worth $927K as of Q2 2026.
  • T. Rowe Price Associates sold 8,783 Ginkgo Bioworks shares in Q2 2026, an estimated $73.5K.
  • Ginkgo Bioworks made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2372 holding.
  • T. Rowe Price Associates first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Ginkgo Bioworks position peaked at $35.6M in Q1 2022.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.